US HealthTech startup Orchid has raised $12 million from Masha Bucher’s Day One Ventures, Prometheus Fund, Starbloom Capital, Refactor Capital, Pebblebed, Conviction Capital and several business angels. The seed round closed in December 2023.
Orchid was founded in 2020 in San Francisco. The collaborators have developed a system for preliminary analysis of couples’ genomes before conception. The company says it has found a way to genomically sequence embryos before transferring them to the uterus during IVF.
The tests help determine which is the healthiest embryo for implantation. It can be used to determine genetic predisposition to diseases such as stroke, schizophrenia, Alzheimer’s disease, breast cancer, diabetes, etc.
Three years ago, Day One Ventures already invested in Orchid in a $4.5 million round.
Author:
Karina Pardaeva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
